New targeted radiation shows promise for tough childhood cancer
Disease control
Terminated
This study tested a radioactive drug called 67Cu-SARTATE in children with high-risk neuroblastoma, a serious nerve cell cancer. The goal was to find the safest dose and see if it shrinks tumors. The trial was stopped early, but results help guide future treatments.
Phase: PHASE1, PHASE2 • Sponsor: Clarity Pharmaceuticals Ltd • Aim: Disease control
Last updated May 14, 2026 12:06 UTC